131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin's lymphoma: radiation dose to the testes.

about

Effects of chemotherapy and radiotherapy on spermatogenesis in humans.

P2860

Q37305907-BD430940-B291-494B-8C55-7A0BF5B70BD1

P2860

131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin's lymphoma: radiation dose to the testes.

Item

http://www.wikidata.org/entity/Q36987727

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

131I-tositumomab myeloablative ...... radiation dose to the testes.

@en

type

Item

label

131I-tositumomab myeloablative ...... radiation dose to the testes.

@en

prefLabel

131I-tositumomab myeloablative ...... radiation dose to the testes.

@en

P1476

131I-tositumomab myeloablative ...... radiation dose to the testes

@en

P2093

Andrew T Shields

http://www.w3.org/2001/XMLSchema#string

Darrell R Fisher

http://www.w3.org/2001/XMLSchema#string

John M Pagel

http://www.w3.org/2001/XMLSchema#string

Joseph G Rajendran

http://www.w3.org/2001/XMLSchema#string

Naoya Hattori

http://www.w3.org/2001/XMLSchema#string

Ted Gooley

http://www.w3.org/2001/XMLSchema#string

P2860

Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.

Effects of testosterone on erectile function: implications for the therapy of erectile dysfunction.

Fluorine-18 fluorodeoxyglucose PET/CT patterns of extranodal involvement in patients with Non-Hodgkin lymphoma and Hodgkin's disease.

A systematic review of the gonadal effects of therapeutic radioactive iodine in male thyroid cancer survivors.

Current options for preservation of fertility in the male.

Do male lymphoma survivors have impaired sexual function?

Hypogonadism following prostate-bed radiation therapy for prostate carcinoma.

MIRD dose estimate report No. 20: radiation absorbed-dose estimates for 111In- and 90Y-ibritumomab tiuxetan.

Radiation therapy induced changes in male sex hormone levels in rectal cancer patients.

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

P304

1225-1231

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MNM.0B013E328358D34B

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ajay K Gopal

Oliver W Press

P577

2012-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22955187

http://www.w3.org/2001/XMLSchema#string

P932

3703155

http://www.w3.org/2001/XMLSchema#string

131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin's lymphoma: radiation dose to the testes.

about

P2860

P2860

131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin's lymphoma: radiation dose to the testes.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932